In the News

Semaglutide discontinuation more common in patients with diabetes plus stroke, CKD

A study of older adults with diabetes who initiated a glucagon-like peptide-1 receptor agonist found that, in the U.S., more than half had discontinued it within a year, with higher discontinuation rates among those with chronic kidney disease (CKD), a history of stroke, or peripheral vascular disease.

Overuse of HbA1c testing may be common in nursing home residents with diabetes

HbA1c levels were tested frequently even in patients not taking medications for their diabetes, those taking medications with low risk for hypoglycemia, and those whose HbA1c levels were in the target range, a Canadian study found.

Role of weight loss in prediabetes remission examined

Whether patients had remission of prediabetes in response to an intensive lifestyle intervention was not determined by whether they lost weight, a post hoc analysis of a trial in Germany found. Those who achieved remission did have different distribution of their adipose tissue, however.

MKSAP quiz: Treatment change after hypoglycemia hospitalization

This month's quiz asks readers to evaluate a 73-year-old woman with a longstanding history of type 2 diabetes mellitus after she was recently hospitalized for hypoglycemia.

Spotlight on tech engagement strategies

Veterans with diabetes appeared to use telehealth for complex care needs, a telemonitoring intervention for Black patients did not improve glycemic control, and an electronic referral system led patients with prediabetes to participate in prevention programs, recent studies showed.

Hospitalists dip into DKA

Protocols using subcutaneous insulin have brought diabetic ketoacidosis (DKA) into the domain of hospitalists.

AI tool assessed body composition, diabetes risk using whole-body MRI

Patients whose MRIs showed high levels of visceral fat or fat as a fraction of skeletal muscle were more likely to develop diabetes, a study using artificial intelligence (AI) found. The results highlight the potential for opportunistic screening by AI, according to the authors.

In insulin-naive T2D, fixed-dose weekly efsitora was noninferior to daily glargine for reducing HbA1c at 52 wk

Efsitora, a weekly insulin, was associated with weight gain in the industry-funded trial, but for patients with inadequate glycemic control on combination therapy for type 2 diabetes (T2D), weekly insulin will likely provide benefits, an ACP Journal Club commentary said.

In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA1c vs. placebo at 40 wk

An industry-funded trial showed that the new oral glucagon-like peptide-1 receptor agonist reduced HbA1c levels by a similar amount as oral semaglutide but less than higher-dose injectable drugs in the class, an ACP Journal Club commentary noted.

In T2D and hypertension, the lower-sodium DASH4D diet reduced SBP more than a higher-sodium comparison diet at 5 wk

The reduction in systolic blood pressure (SBP) seen in this sodium-focused diet trial supports the notion of food as medicine for hypertension, but what diet to recommend to diabetes patients depends on whether blood pressure or glycemic control is the top priority, an ACP Journal Club commentary said.